An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *
Glooko Presents Data on Glucose Management Tool’s Effectiveness During Labor and Delivery
On October 28, Glooko, Inc., a global digital health company focused on glycemic safety and diabetes management across care settings, announced real-world data presented at the Diabetes Technology Society (DTS) meeting on the use of EndoTool IV for intravenous insulin dosing during labor and delivery (L&D).
The poster, “Use of a Computerized Intravenous Insulin Dosing Application in Pregnancy,” evaluated outcomes among pregnant individuals requiring intravenous insulin during L&D, when care teams must manage hyperglycemia while minimizing the risk of hypoglycemia.
The retrospective analysis included 267 individuals across 43 facilities in the 2025 EndoTool IV database. It compared outcomes in individuals with type 1 diabetes with those in individuals with gestational diabetes (GDM) or type 2 diabetes.
Key findings included:
- No instances of severe hypoglycemia (blood glucose <40 mg/dL) were recorded in either patient group.
- Blood glucose <60 mg/dL occurred in 0.63% of readings among individuals with type 1 diabetes and 0.16% among those with type 2 diabetes or GDM.
- Hyperglycemia (blood glucose >180 mg/dL) occurred in less than 10% of readings in either group. Six readings in total exceeded 300 mg/dL.
- These results were achieved within a glucose range of 90–120 mg/dL in 80–90% of patients.
“Labor and delivery represents a uniquely dynamic period for glycemic management, when insulin requirements can change quickly and clinicians need to maintain tight glucose targets while minimizing the risk of hypoglycemia,” said Endocrine Society member Joseph Aloi, MD, section chief, Endocrinology and Metabolism at Advocate Health, Wake Forest University School of Medicine. “These real-world findings are encouraging because they show that personalized intravenous insulin dosing with EndoTool can support tight glycemic control in this population, with no observed instances of severe hypoglycemia across the patients evaluated.”
Diabetes management during pregnancy involves multiple care settings and clinical teams, including outpatient monitoring, inpatient management during labor and delivery, and follow-up after birth. Continuity across these transitions is a focus of Glooko’s glycemic management strategy.
“These real-world findings are encouraging because they show that personalized intravenous insulin dosing with EndoTool can support tight glycemic control in this population, with no observed instances of severe hypoglycemia across the patients evaluated.”
Joseph Aloi, MD, section chief, Endocrinology and Metabolism at Advocate Health, Wake Forest University School of Medicine
Glooko recently expanded its ambulatory platform with GestationalCare™, a pregnancy-specific diabetes management module designed to help care teams review fasting and post-meal glucose patterns, identify patients who may need additional attention, and support care during pregnancy and the postpartum transition. Alongside inpatient technologies such as EndoTool IV, the module forms part of the company’s approach to connecting glycemic management across care settings.
Diabetes management during pregnancy does not begin or end at the hospital door, according to Mark Clements, MD, PhD, chief medical and strategy officer at Glooko. “A person may need close outpatient monitoring throughout pregnancy, precise insulin management during labor and delivery, and continued support as her care transitions postpartum. These data are particularly encouraging because they demonstrate the potential of EndoTool IV within an important inpatient setting while reinforcing our broader vision: giving clinicians the tools and insights they need to support more consistent glycemic management as people move across care settings.”
“Pregnancy is also a powerful example of why a connected glycemic management platform matters,” Clements continued. “The clinical needs change quickly, but the need for timely data, coordinated decision-making and continuity between care teams remains constant. By expanding our capabilities across both ambulatory and inpatient care, we see an opportunity to help reduce fragmentation and support a more seamless approach to diabetes management during pregnancy and beyond.”
